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CASE REPORTS
Buerger’s disease (thromboangiitis obliterans) is a
small-sized and medium-sized vessel vasculitis that is
closely linked to heavy tobacco use. It differs from
other vasculitides in that the serologic markers of
inflammation and autoantibody formation are either
absent or normal. In addition, Buerger’s disease differs
pathologically from other forms of vasculitis in that
there is a progressive organization of a highly inflam-
matory thrombus in the vessel lumen. There is a rela-
tive sparing of vessel wall architecture, and fibrinoid
necrosis is conspicuously absent.1
The disease was once thought to be confined
mainly to the male population, but there are now an
increasing number of reports in female patients.2-4
Of 112 patients who were found to have Buerger’s
disease between 1970 and 1987 at the Cleveland
Clinic Foundation, 23% were women.2 It is unknown
whether the recent increase in the number of female
smokers entirely accounts for this shift in gender
prevalence; however, it is known that the main deter-
minant of disease occurrence and progression is
tobacco use. Buerger’s disease has occasionally been
reported in users of smokeless tobacco (eg, chewing
tobacco, snuff).5 It is believed that Buerger’s disease
may remain active or may progress in subjects who
are exposed to environmental tobacco smoke.1
Patients often are seen with ischemia or claudica-
tion in the arch of the foot, legs, arms, or hands.
There is almost always more than one limb affected.
Shionoya6 showed that two limbs were affected in
16% of the patients, three limbs in 41%, and four
limbs in 43%. Both superficial thrombophlebitis and
Raynaud’s phenomenon occur, each in nearly 40% of
the patients with Buerger’s disease.1,2
The mainstay of therapy is the absolute avoidance
of smoking and exposure to tobacco products. We and
others have demonstrated that, when the patient suc-
cessfully stops smoking, amputations are rare and the
disease often becomes quiescent.2,7 There are times,
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however, when ischemic pain predominates and
patients require potent narcotic analgesics or sympa-
thetic blockade until a smoke-free milieu can exert its
beneficial effects. Data from Europe have shown that
intravenous Iloprost (a prostaglandin analogue)
appears to have some beneficial effects in controlling
ischemic pain and in healing ischemic ulcerations.8 All
other forms of therapy, such as anticoagulation thera-
py, pentoxifylline, and antiplatelet therapy have proven
to be ineffective. Calcium channel blockers may be
effective in reducing the severity of vasospastic
episodes. The success of sympathectomy is unpre-
dictable, but most investigators try it as a last resort in
attempts to heal ischemic ulcers and prevent amputa-
tion. Surgical revascularization is many times not an
option because of disease of the distal target vessels. A
recently published study suggested that gene therapy
with Vascular Endothelial Growth Factor was effective
in healing ischemic ulcerations and relieving rest pain
in patient with Buerger’s disease.9
Implantable spinal cord stimulators have been
used successfully in patients with atherosclerotic and
vasospastic peripheral arterial disease (PAD) for
almost 20 years, but their documented use in patients
with Buerger’s disease is limited.10-12 Herein, we
describe a patient with Buerger’s disease who had dra-
matic regression of ischemic pain with complete heal-
ing of ischemic digital ulcerations after spinal cord
stimulation (SCS).
CASE REPORT
A 56-year-old woman was seen in consultation for
right hand and arm pain and finger tip ulcerations. The
patient had been healthy until the age of 19 years when an
acute, left leg deep vein thrombosis (DVT) and a pul-
monary embolism developed 6 days after the delivery of
her first child. At the age of 23 years, phlebitis developed
in the left calf. Seven years later, the patient had a second
DVT in the left calf. The patient also had an episode of
superficial thrombophlebitis 4 years before presentation to
our clinic. Since this last episode, she has undergone treat-
ment with warfarin.
Nine months before presentation at the Cleveland
Clinic Foundation, the patient was seen at an outside hos-
pital with sudden onset of right arm pain and right hand
pain, pallor, numbness, and coldness. A thrombectomy of
the right brachial artery was performed. One week after
discharge, the patient returned with severe pain in the
right hand and arm. Arteriographic results showed occlu-
sion of the brachial artery at the bifurcation of the radial
and ulnar arteries. The patient underwent a second
thrombectomy in the right brachial, radial, ulnar, and
interosseous arteries. After surgery, the hand was warm
with near-normal pulses in the wrist. The patient was dis-
charged on subcutaneous heparin therapy.
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Seven months before presentation, the symptoms again
returned. Arteriographic results showed radial and ulnar
artery occlusion. The interosseous artery was the single
runoff vessel to the distal right arm, reconstituting small
collaterals at the level of the wrist. At this time, catheter-
directed urokinase therapy was tried without success. The
patient subsequently underwent a brachial artery to ulnar
artery bypass grafting procedure with saphenous vein and
was discharged from the hospital on warfarin therapy.
Ischemic lesions on the right fingertips developed 2
weeks before the patient was first seen in the vascular med-
icine outpatient clinic. The patient noted significant pain
at rest in the right hand and arm. She had been a home-
maker her entire adult life and had a 50 pack/year smok-
ing history but denied smoking for the past 9 months.
Physical examination results were normal except for
ischemic ulcerations on the right thumb, index, and ring
fingers (Fig 1A). Allen’s test performed on the right hand
revealed delayed filling of the palm from both the ulnar
and the radial arteries. Allen’s test results on the left
showed slow filling of the palm from the radial circulation.
The brachial, radial, and ulnar arterial pulses on the right
were not palpable. The pulses in the left arm were normal.
The left dorsalis pedis and posterior tibial arterial pulses
were absent, and the right posterior tibial pulse was
absent. There was no sclerodactyly or telangiectasis.
Arteriographic results of the right arm and hand
showed an occlusion of the distal brachial artery approxi-
mately 6 cm above the elbow. There was an extensive net-
work of collateral vessels across the elbow and extending
into the forearm. Both the ulnar and the radial arteries,
and the venous bypass graft, were occluded. The
interosseous artery was reconstituted in the distal forearm.
Further distally in the forearm were more collateral vessels
reconstituting a portion of the superficial palmar arch.
Single digital arteries extended into the thumb, index, and
fifth fingers. Two digital arteries supplied both the middle
and ring fingers (Fig 2). There was infrapopliteal disease in
the right leg with normal proximal arteries (Fig 3).
A hypercoagulable profile was performed that included
the following: anticardiolipin antibodies, dilute Russell’s
viper venom test, activated protein C resistance, antithrom-
bin III, plasminogen, fibrinogen, and plasma homocysteine
level. Results were normal. The international normalized
ratio was 5.33, and the activated partial thromboplastin
time was 51 seconds. A circulating anticoagulant was
absent. Low values for protein S (23%) and protein C
(51%) were attributed to warfarin therapy. There was no
ergotamine detected in the serum. The scleroderma anti-
body-70 antibody results were negative, the erythrocyte
sedimentation rate was 33 mm/hour, and C-reactive pro-
tein was 2.8 mg/dL. Other marker results for autoanti-
body formation from an outside hospital were negative.
Because we smelled cigarette smoke on the patient
and the disease appeared to be active, a urine nicotine level
was measured. The urine nicotine level was 1240 ng/mL
(values >200 ng/mL indicate active use of a nicotine
product—tobacco or gum), and the urine cotinine level
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was 360 ng/mL. Thus, the question of active smoking
was raised. The patient continued to deny smoking but
did state that she was using nicotine chewing gum.
Transthoracic echocardiographic results were normal.
Results of contrast echocardiogram with agitated saline
solution showed that there was no shunt present. The
patient was continued on warfarin therapy, was placed on
aspirin and amlodipine besylate therapy, and was scheduled
for sympathetic blockade. Ten days later, before sympa-
thetic blockade, the patient was admitted to our institution
for unremitting pain. The finger ulcers were unchanged.
Intravenous heparin and intravenous morphine therapies
via a patient-controlled infusion pump were initiated. The
patient underwent a right stellate ganglion block with no
evidence of improved right hand/arm circulation.
Because there were no viable distal target vessels for
bypass grafting and because the pain incompletely respond-
ed to a sympathetic blockade, a trial of cervical epidural
SCS was performed. There was almost immediate pain
relief and an increase in right hand temperature. One week
later, a permanent cervical epidural spinal cord stimulator
(Quad Plus, Medtronic, Inc, Minneapolis, Minn) with a
pulse generator was implanted with the distal electrode
opposite C3. The patient was removed from the patient-
controlled infusion pump and discharged on oral analgesic
therapy 3 days later. One month after discharge, oral anal-
gesic therapy had been completely discontinued. The pain
had decreased further, the hand was warm, and there was a
complete healing of all the digital ulcers (Fig 1B).
DISCUSSION
The patient described obtained significant relief
from ischemic pain and had digital ischemic ulcer
healing with a spinal cord stimulator. Although this
patient was older than most patients with Buerger’s
disease, there are numerous cases in the literature in
patients older than 45 years.2,13 DVT and pulmonary
embolism had been diagnosed in the patient at age 19
years (37 years before the diagnosis of Buerger’s dis-
ease), and another DVT was discovered at age 26
years. The patient also had episodes of superficial
thrombophlebitis in her early 20s and again 4 years
before her first visit to the Cleveland Clinic
Foundation. There is no way to determine whether
these early episodes were related to Buerger’s disease.
Superficial thrombophlebitis occurs in approximately
40% of patients with thromboangiitis obliterans.2
However, DVT also may occur in patients with
Buerger’s disease.14-16 In Leo Buerger’s original
pathologic description, he states, “if we dissect out
the vessels in these cases, we are struck by the fact that
there is an extensive obliteration of the larger arteries
Fig 1. A, Patient has multiple deep ischemic ulcerations on thumb, index finger, and middle
finger of right hand. There is superficial ulceration on fifth finger (not shown). B, Ischemic
ulcers have completely healed after placement of permanent implantable spinal cord stimulator.
A B
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Fig 2. Diagnostic arteriogram of right arm and hand. Note severe disease below elbow (A-
C). Interosseous artery is visualized (A), but brachial and radial arteries are both occluded (B).
There are multiple occlusions of digital arteries (C).
A
B
C
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and veins… It is interesting to note that the veins
share equally with the arteries in the lesion of occlu-
sion.”14 Allen and Brown15 also described involve-
ment of the anterior and posterior tibial veins and the
popliteal veins in a clinical study of 200 patients with
thromboangiitis obliterans. Although superficial
thrombophlebitis is clearly more common, DVT
occurred in 4.5% of the patients in one large series.16
There are no diagnostic criteria that are uni-
formly accepted by all investigators. The criteria
from the Ministry of Health and Welfare of Japan6
differ from the criteria of published reports in most
western series.1,2,17,18 Papa et al17 advocate a point
system to diagnose definite or probable Buerger’s
disease, and Mills and Porter18 suggest major and
minor criteria. Our patient fulfilled the diagnostic
criteria shown in Fig 4.1 She was a heavy smoker.
She had distal extremity involvement in three
limbs as determined by means of angiography.
There was no proximal source of emboli shown
with transthoracic echocardiography or angiogra-
phy. There was no evidence of atherosclerosis. All
the tests for autoimmune diseases, connective tis-
sue diseases, and hypercoagulable states were
excluded with the appropriate blood tests.
There are no arteriographic findings that are
pathognomonic of Buerger’s disease. It is not uncom-
mon to see bland infrapopliteal artery occlusive dis-
ease as was shown in this case. Although spider or tree
root configurations of the collaterals or corkscrew col-
laterals are suggestive, they are not pathognomonic
(they may be seen in scleroderma, CREST, mixed
Fig 3. Popliteal artery is healthy (A), but there are no named blood vessels below popliteal
artery on this arteriogram of the right leg (B).
A
B
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connective tissue disease, or other causes of small ves-
sel occlusive diseases) and their absence does not rule
out thromboangiitis obliterans.1,19 It is possible that
the conditions seen in Fig 2 could have resulted from
brachial artery thrombosis or embolization, but our
evaluation failed to show evidence for these entities.
Short of a biopsy, we have done everything possible to
rule out diseases that may mimic thromboangiitis
obliterans.
The ischemic pain and ulcer healing were unre-
sponsive to the usual methods of therapy. Most
patients improve with discontinuing smoking, but it
appears that this patient was continuing to use tobac-
co products. The patient obtained no improvement
from oral calcium channel blockers or systemic anti-
coagulation therapy. We and others have demonstrat-
ed that most patients will respond to conservative
therapy and discontinuing cigarette smoking.2,20
However, despite intensive counseling to discontinue
smoking and an aggressive conservative medical pro-
gram, the patient had unremitting pain and ischemic
ulcerations that necessitated continuous intravenous
morphine administration. The patient was not a can-
didate for further surgical or thrombolytic thera-
py.13,21-23 A sympathetic block had no observable
beneficial effects whatsoever, but the response to
implantable SCS was rapid and dramatic.
SCS is performed in most cases in two stages.24 A
temporary (trial) SCS lead is placed percutaneously in
the dorsal aspect of the epidural space opposite the
segments of the spinal cord that control the target
dermatomes. In this case, a four-electrode lead (Quad
Plus) was placed in the cervical epidural space with the
tip of the distal electrode opposite C3. After a suc-
cessful trial on the basis of evidence of improved cir-
culation (increased hand temperature, thermography,
and increased transcutaneous O2 monitoring) and
evidence of decreased pain both subjectively and by
decreased narcotic requirements, a permanent SCS
with a pulse generator implant was performed. The
latter involves an upper thoracic spinal incision in
which the lead is placed in the cervical epidural space
and anchored to the supraspinous ligament. A subcu-
taneous pocket is created in the hip area for the pulse
generator. A connecting wire then is tunneled subcu-
taneously between the lead of the pulse generator.
Augustinsson et al25 advise that spinal cord stim-
ulators should be reserved for those patients for
whom standard therapy fails and in whom surgical
repair is not likely to be successful. Their main target
group for implanting spinal cord stimulators are
those patients with Fontaine class III pain (rest and
night pain without tissue involvement), although, as
detailed in our patient, other groups of patients have
had successful treatment.25
Cook et al26 first published results of spinal cord
stimulator use in cases of PAD in 1976. Since then,
it has become a valuable therapeutic option for
ischemic pain in PAD in those patients in whom
medical management fails or in those patients who
are not candidates for arterial bypass grafting recon-
structive surgery.
The primary goal of SCS is not only ischemic pain
control but also amputation-sparing effects, increased
walking distance, and ulcer healing.10,11,25-27 Young
patients with primarily vasospastic disease have also
undergone treatment.28
SCS creates a field of electrical activity opposite
the dorsal column of the spinal cord, which results in
both pain relief and thermographic evidence of
Fig 4. Algorithm for diagnosis of thromboangiitis obliterans (Buerger’s disease).
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improved circulation in the corresponding der-
matomes. Such effects were explained first by the
Gate Control Theory.29 However, such an explana-
tion is not only simplistic but also fails to explain the
circulatory changes. More recently, SCS has been
shown to stimulate the production of inhibitory neu-
rotransmitter in the spinal cord of experimental ani-
mals. Increased inhibitory neurotransmitters might
explain the decreased symptoms, some in the corre-
sponding dermatomes.30,31
The approximate cost of the spinal cord genera-
tor is $4000, and the lead costs $1200. Although
this may appear to be an expensive method, we
believe that it is cost-effective in the patient who is
properly selected. The goal of SCS is to decrease the
frequency of hospitalizations, avoid amputation,
decrease pain, and improve the quality of life.
Reports of the use of SCS in Buerger’s disease,
however, are sparse. In their 34-patient study,
Augustinsson et al12 demonstrated ulcer healing,
pain control, and limb sparing in patients who
underwent treatment with SCS. Only one patient in
this series had Buerger’s disease, and the complete
details of that case are not in the report. That patient
had intolerable rest pain and a skin ulcer before SCS.
However, after implantation, a mild degree of pain
relief (1+ out of 3+) was noted and amputation of
the affected limb was avoided.
Kumar et al10 reported improved limb circula-
tion in 46 patients with PAD after the implantation
of SCS. Their study included patients with various
causes of PAD, including Buerger’s disease. The
number of patients with Buerger’s disease and the
details of their specific responses to spinal cord stim-
ulators were not included in their publication.
Tallis et al11 reported 10 patients who under-
went SCS for various causes of PAD. Their lone
patient with Buerger’s disease was noted to have a
six-fold increase in walking distance and resolution
of rest pain after the stimulator was placed.
CONCLUSION
When smoking cessation, medications, and sym-
pathectomy fail to relieve ischemic pain in patients
with Buerger’s disease and when surgical revascular-
ization is not a therapeutic option, consideration
should be given to neuromodulation techniques via
stimulation. Advantages of this technique include
being relatively simple, nondestructive, and reversible.
However, it is an expensive method and should be
reserved for patients who have severe, but stable,
symptoms, failed medical management, and are not
candidates for reconstructive bypass grafting surgery.
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